Update: Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency

02:25 PM EDT, 10/16/2026 (MT Newswires) -- (Updates with the stock move in the headline and in the first paragraph.) Omeros (OMER) shares fell 14% in Friday trading after the EU's Committee for Medicinal Products for Human Use again rejected the company's application to market narsoplimab for a rare blood complication that follows stem cell transplants. The committee reaffirmed its June verdict after reexamination, and an eight-member expert group brought in for the review called for outside specialists to study patient-level data to better understand treatment response and survival, the company said. Patient-level data Omeros submitted in August to support the reexamination did not reach the expert group, the company said. Price: 16.19, Change: -2.60, Percent Change: -13.84